Physician profile
David C Terrell
NPI 1811411754
$2,573.47
in general payments reported to CMS, 2019-2025
30 companies · $747 in 2025
The $747 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,434 · 2022: $187 · 2023: $192 · 2024: $13.19 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.64 |
| Education | $135.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $402.83 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $380.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $215.11 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $195.93 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.99 | 2021-2025 | Jardiance |
| Abbvie INC. | $107.94 | 2021-2022 | |
| Amarin Pharma, INC. | $99.88 | 2021 | |
| Mylan Specialty L.P. | $90.90 | 2021 | |
| Phathom Pharmaceuticals, INC. | $79.64 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $67.80 | 2021 | |
| Sanofi-Aventis U.S. LLC | $59.93 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.11 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $52.97 | 2022-2025 | |
| Biogen, INC. | $52.34 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.94 | 2025 | Caplyta |
| Corcept Therapeutics | $46.98 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $46.17 | 2025 | Sunosi |
| Glaxosmithkline, LLC. | $43.33 | 2021 | |
| Grifols USA, LLC | $40.80 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $34.86 | 2021-2022 | |
| Pfizer INC. | $32.97 | 2021-2025 | |
| Abbott Laboratories | $30.74 | 2025 | Jot Dx |
| Merck Sharp & Dohme LLC | $29.76 | 2021 | |
| Sunovion Pharmaceuticals INC. | $27.45 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.61 | 2021 | |
| Dexcom, INC. | $17.24 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $16.80 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.74 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.01 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Terrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.